Literature DB >> 19759232

Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient.

Constance Delaugerre1, Blandine Denis, Gilles Peytavin, Pierre Palmer, Thomas Mourez, Jerôme Le Goff, Jean-Michel Molina, François Simon.   

Abstract

Human immunodeficiency virus (HIV) load is the main marker used to monitor antiviral treatment efficacy and resistance. We report a case of underquantification of HIV type 1 (HIV-1) RNA in plasma and cerebrospinal fluid from an HIV-1 subtype G-infected woman, leading to delayed diagnosis of HIV encephalitis and to the emergence of drug resistance.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19759232      PMCID： PMC2772608          DOI： 10.1128/JCM.00206-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  5 in total

1.  Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.

Authors:  Marie Gueudin; Jean Christophe Plantier; Véronique Lemée; Marie Paule Schmitt; Loic Chartier; Thomas Bourlet; Annick Ruffault; Florence Damond; Muriel Vray; François Simon
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-15       Impact factor: 3.731

2.  Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.

Authors:  M Wirden; R Tubiana; F Marguet; I Leroy; A Simon; M Bonmarchand; Z Ait-Arkoub; R Murphy; A G Marcelin; C Katlama; V Calvez
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

3.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

4.  Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.

Authors:  F Damond; B Roquebert; A Bénard; G Collin; M Miceli; P Yéni; F Brun-Vezinet; D Descamps
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

5.  Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay.

Authors:  Anthony R Oliver; Spyridon F Pereira; Duncan A Clark
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948
  5 in total
  5 in total

1.  Upgraded Cobas Ampliprep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations.

Authors:  M Wirden; R Tubiana; S Fourati; M Thevenin; A Simon; A Canestri; Z Ait-Arkoub; C Soulie; A G Marcelin; C Katlama; V Calvez
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

2.  Sequence conservation of the region targeted by the Abbott RealTime HBV viral load assay in clinical specimens.

Authors:  Gavin A Cloherty; James Rhoads; Thomas P Young; Neil T Parkin; Vera Holzmayer; Lilly Yuen; Carolyn Mullen
Journal:  J Clin Microbiol       Date:  2013-01-23       Impact factor: 5.948

3.  Increasing HIV subtype diversity and its clinical implications in a sentinel North American population.

Authors:  Reed Ac Siemieniuk; Brenda Beckthold; M John Gill
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

4.  Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test and identification of rare polymorphisms potentially affecting assay performance.

Authors:  Michael T Pyne; Katherine L Brown; David R Hillyard
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

Review 5.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.